We made our debut in the “Stock Exchange Company of the Year” ranking a year ago. Yesterday, we once again stood on the podium, adding four more distinctions to our pool of awards. In the 27th edition of the Puls Biznesu ranking, we received the highest scores from analysts and fund managers in the “Growth Prospects” category. We placed third in the “Highest Innovation in Products and Services” and “Investor Relations” categories. In the overall ranking, we are once again in the TOP3.
Pride and satisfaction!
Łukasz Bzdzion and Paweł Wielgus emphasize:
💬 The strength of Bioceltix lies in a team that knows where it is heading and is able to turn ambitious ideas into reality. A long time ago, we made the decision to take on the challenge of developing a veterinary medicinal product containing stem cells, which from the very beginning required an uncompromising approach to quality, the manufacturing process, and completing the full registration pathway. We are on the right track. We are paving new biotechnological paths and are pleased that the market appreciates it.
“Bioceltix on the starting blocks for pharmaceutical millions,” writes Puls Biznesu in today’s article.
Thank you for the distinctions, congratulations to the other leaders of the Polish market, and see you next year!
More about the ranking: https://gsr.pb.pl/